🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. Anlotinib plus Pemetrexed

    Henan Provincial People's Hospital

    Non-squamous Cell Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  3. Anti-LeY-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myeloid Malignancies

    phase 2 mab active

    1 trial

  4. Apatinib

    The First People's Hospital of Lianyungang

    Malignant Ascites

    phase 2 small molecule active

    1 trial

  5. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  6. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial

  7. Azacitidine in Combination With Venetoclax

    The First People's Hospital of Lianyungang

    Hematologic Malignancy

    phase 2 small molecule active

    1 trial

  8. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  9. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  10. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  11. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  12. BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE

    BEONE MEDICINES AUS PTY LTD

    Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

    phase 2 small molecule active

    1 trial

  13. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    B-cell Malignancy

    phase 2 small molecule active

    3 trials

  14. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  15. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  16. BT8009, Zelenectide Pevedotin, PEMBROLIZUMAB

    BICYCLE THERAPEUTICS

    Nectin-4 Expressing Advanced Malignancies.

    phase 2 small molecule active

    1 trial

  17. Bevacizumab

    The First People's Hospital of Lianyungang

    Malignant Pleural Effusion

    phase 2 small molecule active

    1 trial

  18. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

  19. CAN-2409

    Candel Therapeutics

    Malignant Glioma

    phase 2 mab completed

    1 trial

  20. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  21. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  22. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  23. CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  24. CLN-081

    Cullinan Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources